Exact Sciences Executive and Leadership Team

Nassar Nizami, the Chief Information Officer at Exact Sciences, directs the companys technology strategy and infrastructure. Nizami oversees the development and implementation of robust IT systems that support Exact Sciences' mission of early cancer detection and prevention. This leadership involves managing data security, ensuring system scalability, and driving digital transformation across all operational facets. The Chief Information Officer's role is critical in leveraging technology to enhance diagnostic capabilities and streamline clinical decision-making processes for healthcare providers. Nizami ensures that the technological backbone of the company directly supports its innovative screening and diagnostic solutions, facilitating efficient data management and secure access to patient information. By architecting advanced IT frameworks, Nizami enables the company to expand its reach and impact in the healthcare diagnostics sector, driving operational excellence and supporting the continuous improvement of patient care pathways.

Tom Beer, the Multi-Cancer Early Detection Vice President & Chief Medical Officer at Exact Sciences, spearheads the strategic medical direction for groundbreaking multi-cancer early detection initiatives. Beer guides the clinical development and validation of innovative diagnostic tests designed to identify multiple types of cancer at their earliest, most treatable stages. This executive leadership involves translating complex scientific research into actionable clinical applications, ensuring the highest standards of medical accuracy and patient safety. The Multi-Cancer Early Detection Vice President & Chief Medical Officer's responsibilities extend to fostering collaborations with leading medical institutions and researchers to accelerate the adoption of these advanced screening methods. By championing these pioneering efforts, Tom Beer directly contributes to Exact Sciences' commitment to transforming cancer care and improving patient survival rates through proactive, comprehensive early detection strategies.

Durado Brooks, the Associate Chief Medical Officer at Exact Sciences, provides critical medical expertise and leadership to support the companys diagnostic development and commercialization efforts. Brooks collaborates closely with the Chief Medical Officer and other senior leaders to ensure the clinical integrity and efficacy of Exact Sciences' screening and diagnostic solutions. This role involves contributing to the strategic planning of medical affairs, supporting clinical research, and engaging with the medical community to communicate the value of early cancer detection. The Associate Chief Medical Officer's focus is on enhancing patient outcomes by ensuring that the companys innovative testing methods are grounded in sound medical science and meet the evolving needs of healthcare providers. Durado Brooks plays a key part in reinforcing Exact Sciences' position as a leader in healthcare diagnostics by driving medical excellence and supporting the widespread adoption of advanced cancer screening technologies.

Paul Limburg, the Chief Medical Officer, Screening at Exact Sciences, directs the medical strategy and clinical oversight for the companys advanced screening programs. Limburg is instrumental in guiding the development and implementation of innovative diagnostic tools aimed at detecting cancer at its earliest, most treatable stages. This leadership position involves ensuring the scientific rigor and clinical utility of screening solutions, thereby enhancing patient care pathways. The Chief Medical Officer, Screening's responsibilities include collaborating with research teams, medical professionals, and regulatory bodies to advance the field of cancer diagnostics. By focusing on proactive detection, Paul Limburg significantly contributes to Exact Sciences' mission of improving patient outcomes and reducing the burden of cancer through accessible and effective screening technologies. Limburg's expertise drives the clinical validation and market introduction of novel screening methods.